Dr. Irena Melnikova joined the TVM Capital Life Science team in 2008. She is a Principal in the Boston office and assists in the management of TVM Capital investments and due diligence in the United States.
Prior to TVM Capital, she launched and produced “Future in Focus,” a series of syndicated reports for Leerink Swann and was a member of the biopharma investment banking team where she supported due diligence and opportunity assessment activities that resulted in public and private financings as well as M&A transactions.
Prior to Leerink Swann, Dr. Melnikova was a Research Manager at Life Science Insights, a subsidiary of IDC, the leading technology market research company.
As a project leader at TransForm Pharmaceuticals (acquired by Johnson & Johnson), she was responsible for running several programs including Engineered Tissue Constructs and Amyloidoses.
She holds a Ph. D. in Molecular Medicine/Molecular Biology from the University of Texas and an MS with Honors in Chemical Engineering from Russian University of Chemical Technology. Dr. Melnikova is a regular contributor to the “Analyst Couch” section of Nature Reviews in Drug Discovery magazine. She is the co-inventor on a filed patent for methods for identifying conditions affecting a cell state.
To read her most recent article in Nature Review, → please click here.
